Skip to main content
AmigoFish

Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA

From BioCentury This Week · · 26 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

As targeted protein degradation gains momentum, oral selective estrogen receptor degraders (https://www.biocentury.com/article/657916) are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury’s Lauren Martz assesses how the oral SERD landscape is evolving. Washington Editor Steve Usdin then discusses setbacks at FDA for an orphan therapy (https://www.biocentury.com/article/658450) from Disc Medicine and a vaccine from Moderna, and why he is calling (https://www.biocentury.com/article/658404) on life sciences industry leaders to publicly demand the dismissal of Vinay Prasad, FDA’s CSO, CMO, and director of CBER.

View full story: https://www.biocentury.com/article/658455 #TargetedProteinDegradation #OralSERDs #OncologyDrugDevelopment #FDASetbacks #CBER

00:00 - Introduction 03:12 - Oral SERD Spotlight 11:40 - Setbacks at FDA 15:12 - Disc Medicine CRL

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem